



COLORADO

Department of Health Care
Policy & Financing

AGENDA: DUR BOARD MEETING

Health First Colorado, Colorado Medicaid, Drug Utilization Review Board
Department of Health Care Policy and Financing

This will be a virtual attendance-only meeting

Virtual meeting details will be posted and available at <https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board> prior to the meeting.

August 11, 2020

1:00 p.m. – 5:00 p.m. Open Session

DUR Board Members

Michael Noonan, DO (Chair)
Gosia Thomas, PharmD (Vice-Chair)
Miroslav Anguelo, PharmD
Liza Wilson Clauz, PharmD
Allison Blackmer, PharmD
William Lai, PharmD
Alison Shmerling, MD
Scott VanEyck, MD
Mary Wilkerson, MD

CO-DUR Team

Jeffrey Taylor, PharmD (HCPF)
Robert L Page, PharmD, MSPH (CO DUR)
Brandon Utter, PharmD (CO DUR)
Heather Anderson, PhD (CO DUR)
Garth Wright, MPH (CO DUR)
Gina Moore, PharmD, MBA (CO DUR)
Julia Rawlings, PharmD (CO DUR)

Announcing New Chair/Vice Chair

Roll Call / Introductions and Welcome to New Members

Approval of Minutes from May 12, 2020 Meeting

Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest:

- Agenda items must be approved in advance, including requests to present information. Please contact the DUR Pharmacist, Jeff Taylor, at jeffrey.taylor@state.co.us with questions.
- Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours before the meeting.

Open Session:

Unfinished Business and General Orders:

- Colorado Department of Health Care Policy and Financing Updates
- Retrospective DUR Updates
- Quarterly Module Summary
- FDA Updates

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.
www.colorado.gov/hcpf





COLORADO

Department of Health Care Policy & Financing

- Quarterly Drug Utilization Reports

Updates on Business from Last Meeting:

(items included in this section are not scheduled for public testimony or board review as part of this agenda)

- Non-Opioid Analgesics
- Opioids –Long-Acting
- Opioids –Short-Acting
- Tetracyclines
- Angiotensin Modulators and Angiotensin Modulator Combinations
 - ACE Inhibitors, ACE Inhibitor Combinations
 - ARBs, ARB Combinations
 - Renin Inhibitors & Combinations
- Acne Agents
 - Topicals
 - Oral Isotretinoin
- Androgenic Agents
 - Topicals
 - Injectables
 - Orals
- Respiratory Inhalants
 - Inhaled Anticholinergics & Anticholinergic Combinations
 - Inhaled Beta2Agonists (short-acting)
 - Inhaled Beta2Agonists (long-acting)
 - Inhaled Corticosteroids and Combinations
- Mass review drug classes:
 - Skeletal Muscle Relaxants
 - Rosacea Agents, Topical
 - Antihistamines, Newer Generation & Combinations
 - Topical Immunomodulators
 - Phosphate Binders
 - Benign Prostatic Hypertrophy (BPH) Agents
- Nayzilam (midazolam)
- Dupixent (dupilumab)
- Soliris (eculizumab)
- Ergomar (ergotamine)
- Thiola EC (tiopronin)
- Review of Products for Proposed Drug Label Prior Authorization:
 - Ultomiris (ravulizumab)
 - Revcovi (elapegedemase-lvlr)
 - Lumizyme (alglucosidase alfa)

New Business (open for public testimony and board review):

Proposed Criteria for PDL Drug Classes Scheduled for Review:

- Anticonvulsants, Oral
- Stimulants and Related Agents

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.
www.colorado.gov/hcpf





COLORADO

Department of Health Care Policy & Financing

- Contraceptives, Oral
- Diabetes Management Classes – DPP-4 Inhibitors
- Diabetes Management Classes – GLP-1 Analogues
- Diabetes Management Classes – Hypoglycemic Combos
- Diabetes Management Classes – SGLT-2 Inhibitors
- GI Motility, Chronic
- Anticoagulants
- Colony Stimulating Factors
- Newer Hereditary Angioedema (HAE) Agents
- Mass review drug classes*:
 - Bone Resorption Suppression and Related Agents
 - Diabetes Management Classes – Amylin
 - Diabetes Management Classes – Biguanides
 - Diabetes Management Classes – Meglitinides
 - Diabetes Management Classes – TZDs
 - Erythropoiesis Stimulating Agents
 - Prenatal Vitamins
 - Overactive Bladder Agents
 - Ophthalmic Immunomodulators

Proposed ProDUR and Prior Authorization Criteria for Other Selected Products:

- Oriahnn (elagolix, estradiol, norethisterone)
- Palforzia (Arachis hypogaea)
- Oxybryta (voxelotor)
- Oxervate (cenegermin-bkbj)
- Xermelo (telotristat ethyl)
- Palynziq (pegvaliase-pqpz)
- Qbrexza (glycopyrronium)
- Review of Products for Proposed Drug Label Prior Authorization:
 - Galafold (migalastat hydrochloride)
 - Pretomanid
 - Vimizim (elosulfase alfa)

**Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review based on board vote.*

Adjourn

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at jeffrey.taylor@state.co.us or the 504/ADA Coordinator hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

